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ORIGINAL ARTICLE
Bad news itself or just the messenger? The high
mortality of Fusobacterium spp. infections is related
to disseminated malignancy and other comorbidities
Katrine Johannesen1*, Ram Dessau2,3, Ole Heltberg2 and Uffe Bodtger1,3
1Department of Respiratory and Internal Medicine, Naestved Sygehus, Næstved, Denmark; 2Department of
Clinical Microbiology, Slagelse Sygehus, Næstved, Denmark; 3Institute for Regional Health Research,
University of Southern Denmark, Odense, Denmark
Background: Fusobacterium species are pleomorphic, obligate anaerobic gram-negative bacilli. They are
difficult to culture and grow slowly. If antibiotic treatment is initiated prior to blood cultures, the bacteria
might evade detection. This is a comprehensive report on mortality in non-bacteraemia fusobacterial infection.
Methods: Data were collected retrospectively in adults having a positive culture with Fusobacterium spp.
admitted during 20002012 at the medical department. Data on culture specimens, number of cultures,
admission and culture dates, patient age, gender, clinical disease, Charlson’s index of co-morbidity, CRP level
and survival were obtained. For comparison, we traced 60 consecutive, similarly obtained cultures from 2009
to 2010 containing Staphylococcus aureus.
Results: Within a 12-year period, we identified 28 patients with a positive culture of Fusobacterium spp. in
a medical ward serving a population of 220,000. Only a minority (39%) had a positive blood culture, and
54% had focus in respiratory tract or pleura. Overall 6-month mortality was 32%, and unrelated to subspecies,
treatment or anatomic location but significantly related to age 60 years, admission for severe, acute illness,
and comorbidity, especially metastatic malignancy. Comparison between infection with Fusobacterium spp.
and S. aureus showed that Fusobacterium spp. infections were predominantly community acquired, while
S. aureus were both community and hospital acquired. Overall mortality for both bacterial infections increased
significantly with age and current malignant disease. S. aureusinfected patients carried a significantly higher
mortality.
Conclusion: Our data support that Fusobacterium spp. infection is a marker for significant, chronic disease
rather than carrying a poor prognosis per se.
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Summary at a glance: With this study we investigated Fusobacterium spp. infections and the mortality of these, as well as
the comorbidities related to the mortality. We show that malignancy is related to a higher mortality in these infections
specifically.
F
usobacterium spp. are pleomorphic, obligate anaero-
bic gram-negative bacilli that are found as part of the
normal flora in human oropharynx, gastrointestinal
tract and female genitalia. Fusobacterium spp. are difficult
to culture, as they only grow under strict anaerobic conditions.
They grow very slowly: visible growth on a solid medium
is unlikely before 35 days (1). Standard treatment includes
antibiotics  such as penicillin and metronidazole  as well
as drainage (24). If cultures are made after initiation of
routine, antibiotic therapy Fusobacterium spp. may thus evade
detection.
Fusobacterium spp. have been associated with a diversity
of diseases, mainly in the younger population: solitary
lymph node abscess in toddlers, otitis media in children,
peritonsillar abscess or bacterial tonsillitis in adolescents,
sinusitis or tooth infection in children or adolescents,
and dermal, subcutaneous or intraabdominal infections in
adults (5). Fusobacterium necrophorum can, in rare cases,
cause Lemierre’s syndrome, a potentially life-threatening
disease characterised by septic pulmonary embolism
and vena cava thromboembolism (68). An overview of
pathology of Fusobacterium spp. appeared recently (1).
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Why infections with Fusobacterium spp. turn invasive still
remains unanswered, but theories suggest production
of specialised bacterial toxins, or reduced host defence
by viral or bacterial, pharyngeal co-infection (1, 9, 10).
Despite an increase in Fusobacterium spp. bacteraemia
being reported (2), it is still a rare finding: detected in less
than 1% of 22,000 blood cultures (cumulated) (1114),
and in B10% of all pleural empyema cultures (15) in
adults. Empyema per se carries a high mortality (16), and
to the best of our knowledge, there are no comprehensive
reports on mortality in non-bacteraemia fusobacterial
infection.
Methods
Design
A retrospective study of all adult patients (18 years
old) having a positive culture with Fusobacterium spp.,
obtained during a hospital stay at our Department of
Internal Medicine (Naestved Sygehus, Denmark) between
2000 and 2012. As comparator, we randomly selected
a group with cultures positive for Staphylococcus aureus,
obtained during a hospital stay at our Department of
Internal Medicine (Naestved Sygehus, Denmark) between
2009 and 2010.
No patients were culture positive for both bacteria.
Primary endpoint
Mortality at 30 days (1 month) after positive culture was
obtained, stratified by bacteria and clinical data.
Data
Our medical department serves a population of 220,000
inhabitants, including acute admission at all hours.
During the study period, 14,645 subjects had ]1 blood
culture (n16,145) or a pleural effusion culture (n
exactly 1,500). Data on culture specimens, number of
cultures, admission and culture dates, patient age, gender,
clinical disease, Charlson’s index of co-morbidity and date
of death were obtained from medical records. Malignancy
was defined as a histopathological diagnosis of neoplastic
disease (except non-melanoma skin cancer)  known at
the time of culture, or diagnosed during the same hospital
admission as the positive culture  and data were extracted
from the National Database of Pathology. Data on
mortality and malignancy were extracted by 15 December
2014. ‘Acute severe disease’ was defined as treatment in
intensive care units, or any condition with a high risk for
a fatal outcome within days, such as shock of any cause,
large cerebral haemorrhages, acute coronary infarction,
acute respiratory failure, acute renal or hepatic failure.
Two patients (blood culture positive for F. necrophorum)
had missing clinical data (medical records destroyed) but
demographic and microbiologic data and date of death
were known.
Cultures
For blood culture, three BacT/ALERT† bottles (Bio-
Me´rieux, Marcy l’Etoile, France) including one anaerobic
bottle were used, according to the manufacturer, with
5.6 days of incubation and detection. Fusobacterium spp.
were routinely identified by finding growth of gram-
negative rods from the anaerobic sub-culture plates. If
Fusobacterium spp. were suspected, cultures were exam-
ined for kanamycin susceptibility, green fluorescence in
UV-light and smell of butyric acid. If these traits were
present, further phenotypic methods were used for
species identification according to a Danish guideline
(17). However, only F. necrophorum or F. nucleatum were
reported to the species level. Other isolates and isolates
with ambiguous speciation were routinely reported as
Fusobacterium spp., which was considered sufficient detail
for the clinical routine. S. aureus was cultured according
to the routine procedures and was identified simply from
colony morphology, Gram stain and coagulase testing.
Ethics
Data are presented anonymously. Due to study design,
the study did not fall under the jurisdiction of the ethics
committee system. However, the local ethics committee
was notified. The study was registered with the Danish
Data Protection Agency.
Statistics
Statistical analyses were performed using commercially
available software (SPSS version 20, IBM, USA), though
survival analyses and regression analyses were performed
using the survival package in the R software (www.r-
project.org). Discrete data were presented as median
(range), and binary data as percentage. Differences were
examined with non-parametric testing (Mann-Whitney
U-test resp. x2-test). Missing data were omitted from
analyses. Significance was reached when pB0.05. P-values
0.2 are denoted n.s. (not significant) in tables.
Results
Fusobacterium positive cultures
In total, 16,145 culture samples were analysed from
our medical department, and merely 28 samples from
28 patients (male n21, 75%; median age 65 [range
1989] years) were positive for Fusobacterium spp.:
F. necrophorum (blood cultures, n4) including one
patient with Lemierre’s syndrome (described in (7)), and
F. nucleatum (blood culture, n1; pleural effusion, n1).
Culture sites were pleural effusions (n7 out of 1,500;
0.5%), blood cultures (n11 out of 16, 145; 0.07%),
bronchial lavage at bronchoscopy (n7), ascitic fluid
(n1), sputum (n1) and groin abscess (n1).
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Mortality
Mortality was significantly lower in patients’ culture-
positive for Fusobacterium spp. (Table 1, Fig. 1), despite a
higher prevalence of lung abscesses and pleural empyema,
compared to the S. aureuspositive group (1 month: 14
vs. 37%; pB0.05; 6 months: 32 vs. 51%, p0.1)
Overall, Fusobacterium spp. was significantly less
often associated with airway/pleura infections (54 vs.
78%; pB0.05), and even in patients with pleural empyema
or lung abscess, mortality was significantly lower after 1
month compared to S. aureus (0 vs. 33%; pB0.05). No
significant difference in 6-month mortality was observed.
Likewise, 1- or 6-month mortality of non-empyema/non-
lung abscess infection differed insignificantly between the
fusobacteria-positive and the S. aureuspositive group
(data not shown).
Overall prevalence of malignancy did not differ
between groups (Table 1). However, lung cancer was
significantly more prevalent in the fusobacteria-infected
group (19 vs. 3%; pB0.05). Furthermore, the pattern
of bacterial predominance and localisation of primary
cancer differed significantly between patients with
Fusobacterium spp. vs. S. aureus (Pearson x2, pB0.05):
head, throat or oesophageal cancers (4% vs. 10%), uro-
genital cancers (15% vs. 5%), colorectal cancers (4%
vs. 3%) and other malignancy (breast, brain, lymphoma,
pancreas: 0% vs. 9%).
Infection with Fusobacterium spp. predominantly ap-
peared as a community-acquired infection compared
to S. aureus infections with positive cultures obtained at
median 0 (range 022) versus 3 (049) days after hospital
admission (pB0.001).
Table 2 shows factors associated with mortality in
univariate and multivariate analyses.
Using regression analyses, increasing age and malig-
nancy  but neither bacteria subtype (fusobacteria;
S. aureus), pleura empyema/lung abscess, positive blood
culture, gender, nor Charlson’s index of comorbidity ]2 
was significantly associated with mortality (data not
shown).
In the fusobacteria subgroup, antibiotic treatment
was administered to 22 patients; decided by discretion of
the attending physician: intravenous penicillin and metro-
nidazole (n13, 46%), meropenemciprofloxacin;
metronidazole (n2, both treated in Intensive Care
Unit), cefuroximemetronidazole (n2, of whom one
was allergic to penicillin) and penicillin monotherapy
(n5, recovering before culture result was available).
Discussion
In our case series of adult patients with Fusobacterium
spp. infections in a medical ward, we found a considerably
Table 1. Differences in demography, clinic, comorbidity and mortality stratified for focus of infection and type of bacteria
Airway/lung/pleura, n61
Blood/ascites/cavity,
n26
Overall airway
vs. blood
Overall F (n28)
vs. S (n59)
Fusi, n15 Staph, n46 p Fusi, n13 Staph, n13 p p p
Female, n (%) 2 (13%) 20 (44%) 0.06 5 (39%) 5 (39%) n.s. n.s. 0.12
Age, median (range) 65 (4782) 69 (2080) n.s. 64 (1989) 77 (4189) 0.17 n.s. 0.09
Penicillin allergy, n (%) 4 (21%) 3 (6%) 0.033 5 (33%) 0 (0%) 0.16 0.12 0.005
Empyema/lung abscess, n (%) 9 (64%) 3 (7%) 0.0004 2 (17%) 0 (0%) n.s. n.s. 0.00005
Charlson 51, n (%) 6 (40%) 15 (33%) n.s. 5 (39%) 4 (31%) n.s. n.s. n.s.
Charlson, median (range) 2 (06) 2 (06) n.s. 2 (06) 2 (07) n.s. n.s. n.s.
Acute severe disease, n (%) 1 (7%) 25 (54%) 0.002 4 (33%) 7 (54%) n.s. n.s. 0.003
Active cancer, n (%) 6 (43%) 12 (26%) n.s. 4 (33%) 4 (31%) n.s. n.s. n.s.
Lung cancer, n (%) 5 (36%) 2 (4%) 0.006 0 (0%) 0 (0%) n.s. 0.10 0.03
Mortality 1 month, n (%) 0 18 (39%) 0.003 4 (31%) 4 (31%) n.s. n.s. 0.03
Mortality 6 month, n (%) 3 (20%) 24 (52%) 0.038 6 (42%) 6 (42%) n.s. n.s. 0.10
Fig. 1. Survival in Fusobacterium spp. or S. aureus culture
positive patients.
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higher 1- and 6-month mortality (14% vs. 32%) compared
to previously reported overall mortality rates in Danish,
medical wards (5% vs. 13%) with comparable age and
comorbidity (18). However, our data suggest that host
factors such as age and comorbidity, rather than fuso-
bacterial infections per se, predicts mortality  both in
airway/pleural infections and in septicaemia.
In 2012 Castellarin et al. reported an association between
colorectal cancer and local Fusobacterium nucleatum
gene-sequences present in tissue (19). In our study, color-
ectal cancer was a rare finding but our data suggest a
clinically meaningful association between cancer anatomy
and bacterial culture. S. aureus was more prevalent in
cancers related with dysphagia, whereas Fusobacterium spp.
was more prevalent in patients with disrupted mucosal
barriers such as neoplasia in lung or urogenital tract (20, 21).
Few data exist on fusobacterial pleural empyema (15)
but overall empyema mortality averages 2040% (16).
Four recent, retrospective series addressed mortality in
patients with Fusobacterium spp. bacteraemia: 3-month
mortality was 11% (13), 21% (14), 31% (12) and 41% (11).
Despite differences in study populations (medical vs.
surgical vs. ICU wards), all studies support our findings
that Lemierre’s syndrome is a rare manifestation of
fusobacterial infection, and that Fusobacterium spp. infection
mortality is primarily associated with age and comorbidity,
rather than the anatomic location of Fusobacterium
spp. infection, or treatment (4, 1114). In our study,
Fusobacterium spp. was associated with lower mortality
at 1 and 6 months compared to a randomly selected
population (size: 2n fusobacteria-positive patients)
culture positive for S. aureus, supporting that fusobacteria
infections may be controlled in the acute setting, but
should alert the medical team to possible, predisposing
disorders. We chose S. aureus as comparator as it is
a well-described, common pathogen (and everyday clini-
cal challenge) found in the same compartments as
fusobacteria (22). By choosing a single pathogen as
comparator, we kept the head-to-head analyses simple;
however, Staphylococcus has several immune evasion
strategies which might confer the difference in early death
(23) (Table 1).
A reliable in vivo assessment of treatment modalities
would require a controlled study  hampered by the
rarity of this disease entity. Only one other study has been
looking at all Fusobacterium spp. regardless of anatomi-
cal location of infection: Pett et al. identified 18 patients
in the United Kingdom between 1991 and 2013; however,
94% had bacteraemia, and the median age was lower.
They found high mortality rates in the elderly and sick,
and low (0%) in the young and/or F. necrophorum
infections of the head/neck region (4).
We found a comparable, low prevalence rate of
Fusobacterium spp.positive blood cultures, but a much
lower prevalence of Fusobacterium spp. pleural effusions
(4). A policy in our department of microbiological
examination of all pleural effusions  even those with a
low a priori suspicion of infection  would tend to increase
the denominator, decrease the prevalence. As fusobacteria
are fastidious bacteria, culture facilities will determine
successful detection rate. As in previous studies, we identi-
fied only a small Fusibacterium spp. positive patient
cohort. Despite the low patient number, it seems unques-
tionable that age and underlying medical of conditions 
acute or chronic  have a major impact, resulting in a
decreased host defence and increased permeability of
mucosa, precipitating the pathogenic potential of
Fusobacterium spp., as an opportunistic pathogen (24).
The strength of the current study is the consistency and
integrity of data: only one microbiological department and
one clinical department with no loss of patients due to a
unique person identification system. Despite the consis-
tency of data, the major weakness of the study remains the
small sample size. Detailed microbiological information
Table 2. Differences in demography, clinic, comorbidity and 6-month mortality in patients dead vs. alive 1 month after being
culture-positive for fusobacteria or Staphylococcus aureus
Dead within 1 month, n61 Alive after 1 month, n26 p
Female, n (%) 22 (36%) 10 (39%) n.s.
Age, median (range) 63 (1986) 77 (5189) B0.0005
Fusobacterium spp., n (%) 15 (25%) 13 (50%) 0.02
Penicillin allergy, n (%) 7 (10%) 5 (16%) n.s.
Empyema/lung abscess, n (%) 12 (21%) 2 (8%) n.s.
Charlson 51, n (%) 5 (19%) 25 (41%) 0.051
Charlson, median (range) 2 (07) 3 (16) 0.003
Acute severe disease, n (%) 20 (80%) 17 (28%) B0.0005
Active cancer, n (%) 18 (30%) 8 (32%) n.s.
Lung cancer, n (%) 0 (0%) 7 (12%) 0.10
Airway/lung/pleura, n (%) 18 (69%) 43 (71%) n.s.
Mortality 6 month, n (%) 100 (100%) 13 (21%) B0.000001
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on Fusobacterium spp. except F. necrophorum or
nucleatum  was not possible due to the retrospective
design. A prospective study would provide more detailed
data, but would be challenging due to the low prevalence
of Fusobacterium spp. A controlled, clinical study of
selected antibiotics may be considered, although arduous.
In conclusion, Fusobacterium spp. seems to be a
messenger of clinically significant, acute or chronic illness,
rather than implying pathogen-specific therapeutic chal-
lenges for the clinician.
In this retrospective and descriptive study, we found
that infections with Fusobacterium spp. were rare, and
mortality was related to comorbidity, primarily advanced
or metastatic malignancy. Mortality was inferior to that
observed in comparable patients infected with S. aureus.
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